Festival of Biologics 2026 has ended. This guide stays up as the record of who was there. Next: Festival of Biologics 2027, Oct 5–7, 2027 in Basel
Immunotherapy and oncology at Festival of Biologics 2026
Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website
44 organizations at Festival of Biologics 2026 present work in immunotherapy & oncology: 18 drug developers, 14 academic, government and non-profit bodies and 12 suppliers and service providers. Between them they bring 100 presentations to the program. Most represented: Novartis, ETH Zurich and Ichnos Glenmark Innovation. As of Sep 26, 2026.
| Organization | Festival of Biologics 2026 Attendance |
|---|---|
Novartis Basel, Switzerland | |
Global pharmaceutical company whose contract manufacturing arm offers CDMO services for biologics, small molecules, cell and gene therapy, and fill-finish. | Booth Exhibiting at Booth 185 Keynote Tue Oct 13 09:10 Biotechnology, the Renaissance How advances in biology, AI and new treatment types are converging to change what medicine can do for patients. Chair Tue Oct 13 11:25 Chair Tue Oct 13 11:25 Chair Tue Oct 13 11:25 Talk Tue Oct 13 11:30 Panel Tue Oct 13 12:20 Chair Tue Oct 13 14:05 Talk Tue Oct 13 14:50 Intensified Upstream Processing: Fed‑Batch and Perfusion Options for Robust Scale-Up Ways to get more protein from cell cultures by feeding them steadily or continuously, and how to scale that up reliably. Talk Tue Oct 13 15:10 Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. Talk Tue Oct 13 15:30 Chair Tue Oct 13 16:45 Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. Talk Tue Oct 13 17:30 What AI can do – or not – in Patient Engagement What AI can and cannot do when drug developers involve patients in research, and how to measure whether that involvement helps. Chair Wed Oct 14 11:25 Chair Wed Oct 14 11:25 Talk Wed Oct 14 12:10 Talk Wed Oct 14 12:30 Bovine AAV – a promising vector for pulmonary gene therapy Early results from using a cattle adeno-associated virus to deliver gene therapy to the lungs, including how immune systems recognise it. Talk Wed Oct 14 12:30 Chair Wed Oct 14 14:05 Talk Wed Oct 14 14:30 Commercial Considerations for CAR-T Therapy: Lessons Learned from Recent Blockbusters What makes CAR-T cancer therapies hard to sell worldwide, from complex manufacturing and shipping to getting treatment centres and payers ready. Talk Wed Oct 14 15:30 When the Target Moves: Building Robust DSP Through Science, Monitoring, and Learning Why purification steps that once worked can start failing when the material feeding them changes, and how monitoring catches that early. Chair Wed Oct 14 16:45 Chair Wed Oct 14 16:45 Talk Wed Oct 14 16:50 Talk Wed Oct 14 17:30 Protein Quality as a Critical Factor in Target Interference Assessment for Bioanalytical Assays How the quality of a lab-made protein can distort tests that check whether patients make antibodies against a biologic drug. Talk Wed Oct 14 17:50 An Oligonucleotide Program in Late-Stage Clinical Trials Lessons from keeping an anti-drug antibody test working for a cholesterol-lowering siRNA drug through late trials and a handover to a partner lab. Keynote Thu Oct 15 09:05 From Strategy to Delivery: Aligning Bioanalytical Innovation and Execution Across Clinical Phases How to decide what to measure, when and why, as biologic drugs move from early studies into late-stage clinical trials. Talk Thu Oct 15 09:40 Chair Thu Oct 15 11:15 Chair Thu Oct 15 11:15 |
ETH Zurich Zurich, Switzerland | |
Talk Tue Oct 13 17:50 Chair Wed Oct 14 14:05 Talk Wed Oct 14 15:10 High-Throughput Mechanical Phenotyping of Protein–Protein Interactions A faster way to measure how much pulling force protein pairs can withstand, which can differ from how tightly they bind. Talk Thu Oct 15 12:20 Allogeneic T cells synergising with bispecific antibodies achieve superior Antitumor responses Donor T cells engineered to be activated by two-target antibodies without attacking the patient, tested for stronger anti-tumour responses. Talk Thu Oct 15 12:40 | |
IG Ichnos Glenmark Innovation New York, NY | |
Talk Tue Oct 13 14:50 BEAT®: A Platform to Advance Developable Multispecific Therapeutic Antibodies to the Clinic A platform for building antibodies that grip several targets at once, using a shared light chain and pairing ideas borrowed from T-cell receptors. Chair Wed Oct 14 09:00 Chair Wed Oct 14 14:05 Talk Wed Oct 14 15:30 Talk Thu Oct 15 11:40 | |
P Philochem Otelfingen, Switzerland | |
Philogen's Swiss research subsidiary, developing antibody-cytokine fusions and small-molecule ligands for cancer therapy. | Talk Wed Oct 14 15:10 Talk Wed Oct 14 17:50 Advancing stable cell line development for production of therapeutic antibodies Comparing random gene insertion with placing genes at chosen spots in the genome to get steadier antibody production from cell lines. Talk Thu Oct 15 09:20 Talk Thu Oct 15 11:20 Charge Variants characterization of a noncovalent dimeric fusion protein How to measure the different charged forms of a fusion protein whose two halves are not chemically bonded, unlike a standard antibody. |
Find buyers in immunotherapy & oncology
Tell us what you sell and we’ll find the people at organizations working on immunotherapy & oncology most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Festival of Biologics 2026 by
- Antibody & protein engineering 67
- AI & computational design 38
- Bispecifics & multispecifics 13
- ADCs & armed antibodies 18
- Immunotherapy & oncology 44
- Cell & gene therapy 28
- Therapeutic vaccines 13
- Peptides & GLP-1 7
- Bioprocessing & manufacturing 87
- CMC, formulation & analytics 58
- Clinical development 45
- Regulation & market access 40
Not affiliated with or endorsed by the Festival of Biologics or its organizers. Submit a correction